ϳԹ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • ϳԹ News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jul 22 2026 9:15 AM

Full Issue

GLP-1 Use Linked To Fewer Long-Term Sick Days From Work, Study Finds

According to a study by the National Bureau of Economic Research, researchers noted a 17% decrease in long-term sick leave among Danish workers who used GLP-1s compared with those who didn't use the medications. Also: Novo Nordisk sues Eli Lilly; and more.

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. (Cerullo, 7/21)

The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly, accusing its arch-rival of misleading advertising. Lilly and Novo are the market leaders in GLP-1 drug sales, controlling the lion's share of the surging segment. (Bomey, 7/21)

More health and wellness news —

Long-term exposure to residential road traffic noise was associated with an increased risk of Parkinson's disease, a study of more than 3 million adults in Denmark showed. (George, 7/21)

People who frequently watch television in midlife may be more likely to develop brain changes associated with memory problems, cognitive decline and dementia later in life, according to new research. The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggests that what people do while sitting may matter just as much as how long they spend sitting. (Azzurra Volpe, 7/21)

A University of Florida study is shedding new light on the biological changes linked to adolescent idiopathic scoliosis, an abnormal curvature of spine found in many children. (Mayer, 7/21)

Peptide researcher Joshua Kritzer explains why mouse studies and online testimonials aren't enough to prove a treatment is safe or effective. (Talpos, 7/21)

Sanae Takaichi has said she gets just “zero to three hours” of sleep a night, prompting a debate in the country over work-life balance and the hazards of sleep deprivation. (Hernández and Ueno, 7/22)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 22
  • Tuesday, July 21
  • Monday, July 20
  • Friday, July 17
  • Thursday, July 16
  • Wednesday, July 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ϳԹ
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF